2-(6-methylpyridin-2-yl)-N-(pyrimidin-4-yl)quinazolin-4-amine | 733806-90-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(6-methylpyridin-2-yl)-N-(pyrimidin-4-yl)quinazolin-4-amine
• 英文别名: 2-(6-methylpyridin-2-yl)-N-pyrimidin-4-ylquinazolin-4-amine
• CAS: 733806-90-1
• 化学式: C₁₈H₁₄N₆
• 分子量: 314.349
• InChiKey: NTFZYTHOGNVBQR-UHFFFAOYSA-N

物化性质

• 沸点：
  456.8±45.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氨基嘧啶 、 4-chloro-2-(6-methyl-pyridin-2-yl)-quinazoline 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 2-(6-methylpyridin-2-yl)-N-(pyrimidin-4-yl)quinazolin-4-amine
  参考文献：
  名称：

  Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors

  摘要：

  Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid). (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.087

文献信息

• [EN] CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS<br/>[FR] PYRIDINES ET PYRIMIDINES CONDENSEES ET LEUR UTILISATION EN TANT QUE LIGANDS DU RECEPTEUR ALK-5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004065392A1

  公开（公告）日：2004-08-05

  Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.

  治疗上有效的取代喹啉和喹唑啉化合物，其公式（I）中X是N或CH，Y是NH、N（烷基）或NH-CH2，R2和R3是特定的杂环，其在治疗中的用途，特别是在治疗或预防转化生长因子β（TGF-β）过度表达的疾病中的用途，以及用于此类治疗的药物组合物被披露。
• Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
  作者：F. Gellibert、M.-H. Fouchet、V.-L. Nguyen、R. Wang、G. Krysa、A.-C. de Gouville、S. Huet、N. Dodic

  DOI：10.1016/j.bmcl.2009.02.087

  日期：2009.4

  Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid). (c) 2009 Elsevier Ltd. All rights reserved.